MiR-146a down-regulates inflammatory response by targeting TLR3 and TRAF6 in Coxsackievirus B infection.


Journal

RNA (New York, N.Y.)
ISSN: 1469-9001
Titre abrégé: RNA
Pays: United States
ID NLM: 9509184

Informations de publication

Date de publication:
01 2020
Historique:
received: 20 05 2019
accepted: 28 10 2019
pubmed: 5 11 2019
medline: 29 4 2020
entrez: 3 11 2019
Statut: ppublish

Résumé

Coxsackievirus B (CVB) is the major cause of human myocarditis and dilated cardiomyopathy. Toll-like receptor 3 (TLR3) is an intracellular sensor to detect pathogen's dsRNA. TLR3, along with TRAF6, triggers an inflammatory response through NF-κB signaling pathway. In the cells infected with CVB type 3 (CVB3), the abundance of miR-146a was significantly increased. The role of miR-146a in CVB infection is unclear. In this study, TLR3 and TRAF6 were identified as the targets of miR-146a. The elevated miR-146a inhibited NF-κB translocation and subsequently down-regulated proinflammatory cytokine expression in the CVB3-infected cells. Therefore, the NF-κB pathway can be doubly blocked by miR-146a through targeting of TLR3 and TRAF6. MiR-146a may be a negative regulator on inflammatory response and an intrinsic protective factor in CVB infection.

Identifiants

pubmed: 31676570
pii: rna.071985.119
doi: 10.1261/rna.071985.119
pmc: PMC6913124
doi:

Substances chimiques

Cytokines 0
Intracellular Signaling Peptides and Proteins 0
MIRN146 microRNA, human 0
MicroRNAs 0
NF-kappa B 0
TLR3 protein, human 0
Tifab protein, human 0
Toll-Like Receptor 3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-100

Informations de copyright

© 2020 Fei et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.

Références

Biochem Biophys Res Commun. 2018 Jun 7;500(3):744-750
pubmed: 29679565
Curr Top Microbiol Immunol. 2008;323:177-98
pubmed: 18357770
RNA Biol. 2014;11(7):808-16
pubmed: 24921242
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40
pubmed: 19193853
Bratisl Lek Listy. 2016;117(7):376-80
pubmed: 27546538
Nucleic Acids Res. 2013 Apr 1;41(6):3760-71
pubmed: 23389951
PLoS One. 2011;6(8):e23837
pubmed: 21887328
Expert Rev Proteomics. 2014 Feb;11(1):21-9
pubmed: 24351021
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
J Immunol. 2005 Oct 15;175(8):5314-23
pubmed: 16210637
Nature. 2008 Feb 28;451(7182):1125-9
pubmed: 18278031
Cell Mol Life Sci. 2013 Dec;70(23):4631-44
pubmed: 23811937
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
pubmed: 16885212
Evid Based Complement Alternat Med. 2014;2014:950817
pubmed: 24963331
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Intervirology. 2011;54(5):268-75
pubmed: 21242657
J Immunol. 2011 Nov 15;187(10):5320-7
pubmed: 21998457
Mol Ther Nucleic Acids. 2017 Jun 16;7:335-338
pubmed: 28624209
Immunity. 2010 Mar 26;32(3):305-15
pubmed: 20346772
Rev Med Virol. 2011 Mar;21(2):67-77
pubmed: 21312311
Medicine (Baltimore). 2017 Apr;96(17):e6764
pubmed: 28445307
J Gen Virol. 2010 May;91(Pt 5):1245-55
pubmed: 20071487
Intervirology. 2013;56(2):104-13
pubmed: 23183417
Nat Commun. 2014;5:3344
pubmed: 24561744
Trends Mol Med. 2017 Jan;23(1):80-93
pubmed: 27989642
BMB Rep. 2016 Jun;49(6):311-8
pubmed: 26996343
J Virol. 2008 Feb;82(4):2033-7
pubmed: 18057248
Clin Microbiol Rev. 2003 Oct;16(4):637-46
pubmed: 14557290
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncotarget. 2016 Sep 13;7(37):59287-59298
pubmed: 27494902
Arthritis Res Ther. 2014 Jan 14;16(1):R9
pubmed: 24423102
PLoS One. 2017 Oct 3;12(10):e0185819
pubmed: 28973047
Viruses. 2018 Dec 05;10(12):
pubmed: 30563052
Braz J Infect Dis. 2015 Sep-Oct;19(5):510-6
pubmed: 26342975
Nat Commun. 2013;4:1833
pubmed: 23673618
J Hematol Oncol. 2012 Mar 27;5:13
pubmed: 22453030
Future Microbiol. 2015;10(4):629-53
pubmed: 25865198
J Immunol. 2007 Oct 15;179(8):5082-9
pubmed: 17911593
PLoS One. 2012;7(9):e46515
pubmed: 23029542
Scand J Gastroenterol. 2009;44(11):1332-9
pubmed: 19891584
Nat Rev Immunol. 2011 Mar;11(3):163-75
pubmed: 21331081
Antiviral Res. 2012 Feb;93(2):270-279
pubmed: 22197249

Auteurs

Yanru Fei (Y)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Anita Chaulagain (A)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Tianying Wang (T)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Yang Chen (Y)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Jinchang Liu (J)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Ming Yi (M)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Ying Wang (Y)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Yike Huang (Y)

Department of Cell Biology, Harbin Medical University, Harbin 150081, China.

Lexun Lin (L)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Sijia Chen (S)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Weizhen Xu (W)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Lei Tong (L)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Xiaoyu Wu (X)

Department of Cardiology, The First Hospital of Harbin Medical University, Harbin 150001, China.

Dechao Zhao (D)

Department of Cardiology, The First Hospital of Harbin Medical University, Harbin 150001, China.

Fengmin Zhang (F)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Wenran Zhao (W)

Department of Cell Biology, Harbin Medical University, Harbin 150081, China.

Zhaohua Zhong (Z)

Department of Microbiology, Harbin Medical University, Harbin 150081, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH